zoledronska kislina - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

zoledronic acid 5mg/100 millilitre solution for infusion

cipla (eu) limited - zoledronic acid monohydrate - solution for infusion - 5mg/100 millilitre - biphosphonates

zoledronic acid fair-med 5mg/100ml solution for infusion

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - zoledronic acid, monohydrate - solution for infusion - zoledronic acid monohydrate 5 mg - drugs for treatment of bone diseases

Canada - English - Health Canada

act zoledronic acid concentrate solution

actavis pharma company - zoledronic acid (zoledronic acid monohydrate) - solution - 4mg - zoledronic acid (zoledronic acid monohydrate) 4mg - bone resorption inhibitors

United States - English - NLM (National Library of Medicine)

zoledronic acid- zoledronic acid injection, solution, concentrate

par pharmaceutical companies, inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl=ca in mg/dl + 0.8 (4.0 g/dl - patient albumin [g/dl]). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see adverse reactions (6.2) ].